Back to Search
WILLIAM PAO, PHARMD
PHARMD
Pharmacist
NPI: 1730796434Individual
Specialties, Licenses & Credentials
PharmacistPrimary
Pharmacist
Code: 183500000X
81672(CA)
Research & Publications (20)
Defining clinically relevant molecular subsets of lung cancer.
PMID 17093937·Cancer Chemother Pharmacol·2006
6-review
Epidermal growth factor receptor mutations, small-molecule kinase inhibitors, and non-small-cell lung cancer: current knowledge and future directions.
PMID 15767641·J Clin Oncol·2005
6-review
Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain.
PMID 15737014·PLoS Med·2005
5-case
KRAS mutations and primary resistance of lung adenocarcinomas to gefitinib or erlotinib.
PMID 15696205·PLoS Med·2005
8-other
'Targeting' the epidermal growth factor receptor tyrosine kinase with gefitinib (Iressa) in non-small cell lung cancer (NSCLC).
PMID 14757534·Semin Cancer Biol·2004
6-review
EGF receptor gene mutations are common in lung cancers from "never smokers" and are associated with sensitivity of tumors to gefitinib and erlotinib.
PMID 15329413·Proc Natl Acad Sci U S A·2004
8-other
Use of avian retroviral vectors to introduce transcriptional regulators into mammalian cells for analyses of tumor maintenance.
PMID 12857957·Proc Natl Acad Sci U S A·2003
7-preclinical
Use of epidermal growth factor receptor/Kirsten rat sarcoma 2 viral oncogene homolog mutation testing to define clonal relationships among multiple lung adenocarcinomas: comparison with clinical guidelines.
PMID 19376842·Chest·2010
4-observational
PTEN loss contributes to erlotinib resistance in EGFR-mutant lung cancer by activation of Akt and EGFR.
PMID 19351834·Cancer Res·2009
8-other
The tyrosine phosphatase PTPRD is a tumor suppressor that is frequently inactivated and mutated in glioblastoma and other human cancers.
PMID 19478061·Proc Natl Acad Sci U S A·2009
8-other
An integrated genomic analysis of lung cancer reveals loss of DUSP4 in EGFR-mutant tumors.
PMID 19525976·Oncogene·2009
8-other
Genomic and mutational profiling to assess clonal relationships between multiple non-small cell lung cancers.
PMID 19671847·Clin Cancer Res·2009
8-other
Morphologic features of adenocarcinoma of the lung predictive of response to the epidermal growth factor receptor kinase inhibitors erlotinib and gefitinib.
PMID 19260752·Arch Pathol Lab Med·2009
8-other
EML4-ALK: honing in on a new target in non-small-cell lung cancer.
PMID 19667260·J Clin Oncol·2009
8-other
Frequency and distinctive spectrum of KRAS mutations in never smokers with lung adenocarcinoma.
PMID 18794081·Clin Cancer Res·2008
8-other
Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib.
PMID 18981003·Clin Cancer Res·2008
8-other
Acquired resistance to epidermal growth factor receptor kinase inhibitors associated with a novel T854A mutation in a patient with EGFR-mutant lung adenocarcinoma.
PMID 19010870·Clin Cancer Res·2008
5-case
Genetic predictors of MEK dependence in non-small cell lung cancer.
PMID 19010912·Cancer Res·2008
8-other
Data courtesy of the U.S. National Library of Medicine (NLM). Ltrl is not affiliated with or endorsed by NLM.
Contact & Hours
- Address
- 1750 STORY RD, T1984
SAN JOSE, CA 95122 - Phone
- (408) 273-0055
Quick Facts
- NPI
- 1730796434
- Entity Type
- Individual
- Gender
- Male
- Medicare
- Not confirmed
- Specialties
- 1
- Locations
- 1
- Publications
- 20
Are you this provider?
Claim Your Profile